clinical trial · NCT07446101
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
Eli Lilly and Company·phase1·recruiting·n = 450
HealthyMirikizumab
brief summary
The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.
started
Mar 24, 2026
primary completion
Feb 1, 2027
completion
Feb 1, 2027
last updated
Apr 20, 2026
official title
An Adaptive Two-Stage Bioequivalence Study of Subcutaneous Injections of Mirikizumab Solution in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol